Agios' stock drops after disclosing new liver-related safety warning in filing to FDA
Agios Pharmaceuticals on Monday saw its stock price drop by more than 24% as it disclosed that its oral candidate for the blood disorder thalassemia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
